Lycera Corp. recently announced the initiation of its LYC-30937-EC (Enteric Coated) Phase 2 clinical trial for the treatment of patients who are suffering from ulcerative colitis (UC). Read More »

Allergen plc announced last week that it has reached an agreement to acquire Vitae Pharmaceuticals Inc. for $21 per share in cash. Read More »

AcelRx Pharmaceuticals Inc. announced the release of the results of its Phase 3 ARX-04 trial during a conference call and through a webcast on Sept. 15. Read More »

Cumberland Pharmaceuticals has announced that it has initiated a Phase II clinical program involving Portaban. Read More »

The experience of Mylan, the pharmaceutical company under fire for hiking the price of a life-saving allergy medicine, reinforces the importance of competition in the marketplace, one of the country’s largest pharmacy benefit managers said. Read More »

The National Pharmaceutical Council (NPC) has announced that it will host a conference for health care stakeholders to discuss the effect of medical treatment on patient care and how the value of these treatments can be measured. Read More »

Express Scripts last week announced the launch of its Inflammatory Conditions Care Value Program, an all-inclusive method of controlling costs and improving care for individuals who have inflammatory conditions such as rheumatoid arthritis, psoriasis and Crohn’s Disease. Read More »

The trial will focus on idiopathic sudden sensorineural hearing loss (ISSNHL), also called sudden deafness. Read More »

Portola Pharmaceuticals Inc. recently received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) submitted for AndexXa (andexanet alf Read More »

The American Society of Health-System Pharmacists (ASHP) has announced a collaboration with the Institute for Safe Medication Practices (ISMP) for the development of a Medication Safety Certificate Program that will begin in the spring of next year. Read More »

CVS Health today announced that all CVS Pharmacy locations in the state of Washington now have naloxone, the opioid overdose-reversal medicine, available for patients without the need of a prescription. Read More »

Dr. Levi Garraway has been appointed SVP of Global Development & Medical Affairs for the oncology business at Eli Lilly and Company. Read More »

Stratice Healthcare, a health care IT leader providing electronic ordering technology connecting home and durable medical equipment and supplies (HME/DME) providers with medical offices and hospital systems, has announced that it has come to terms on an agreement with CMB Solutions, a nationwide patient support and contact service provider for the home medical equipment industry. Read More »

CVS Health this week announced a collaboration with the YMCA of the USA for the expansion of the Diabetes Prevention Program and the LIVESTRONG Foundation at the YMCA program. Read More »

AbbVie, a biopharmaceutical company that operates worldwide, has announced its 2016 Thriving Student Scholarship Contest. Read More »

Galena Biopharma Inc. as announced that the preclinical data from its NeuVax program was revealed during a presentation given Tuesday at the Progress in Vaccination Against Cancer (PIVAC) Conference that is being held in Winchester, England. Read More »

Recent survey results conducted by North Star Opinion Research and released by an industry association confirm that 60 percent of U.S. employers believe new federal oversight would lead to higher prescription-drug costs. Read More »

A single industry-sponsored meal is enough to sway a doctor to prescribe a brand-name drug rather than a cheaper but just as effective generic, a study by the University of San Francisco has found. Read More »

Morphotek Inc. recently entered a Sponsored Research Agreement (SRA) along with Fox Chase Cancer Center (FCCC) that will lead to the expansion of its efforts to research how efficient immune-based therapies are in relation to the immunosuppressive effects that are caused by tumor shed antigens. Read More »

Antibody product is a potential treatment for Huntington's Disease. Read More »